Table 2. Bioactivity of pure compounds at different doses.
| Stimulus | Dose (µg) | Treatment median (s) | Negative control median (s) | P | Treatment/negative control |
| EUG 1 | 1 | 17.5 | 24.0 | n.s. | 0.7 |
| EUG 1 | 10 | 22.5 | 14.0 | n.s. | 1.6 |
| EUG 1 | 100 | 128.0 | 9.5 | <0.01 | 13.5 |
| EUG 1 | 1000 | 192.5 | 12.0 | <0.01 | 16.0 |
| EUG 2 | 10 | 7.5 | 14.0 | n.s. | 0.5 |
| EUG 2 | 100 | 182.0 | 9.5 | <0.01 | 19.2 |
| EUG 2 | 1000 | 193.5 | 12.0 | <0.01 | 16.1 |
| EUG 3 | 10 | 18.0 | 14.0 | n.s. | 1.3 |
| EUG 3 | 100 | 80.0 | 9.5 | <0.01 | 8.4 |
| EUG 3 | 1000 | 187.0 | 12.0 | <0.01 | 15.6 |
| SYR | 10 | 20.0 | 18.5 | n.s. | 1.1 |
| SYR | 100 | 184.0 | 18.5 | <0.01 | 9.9 |
| SYR | 1000 | 195.5 | 18.0 | <0.01 | 10.9 |
| ADP | 1 | 12.5 | 12.0 | n.s. | 1.0 |
| ADP | 10 | 166.0 | 16.5 | <0.01 | 10.1 |
| ADP | 100 | 192.0 | 19.5 | <0.01 | 9.8 |
| ADP | 1000 | 197.5 | 16.5 | <0.01 | 12.0 |
| CAT | 1 | 12.0 | 12.0 | n.s. | 1.0 |
| CAT | 10 | 53.5 | 12.0 | <0.01 | 4.5 |
| CAT | 100 | 193.0 | 12.0 | <0.01 | 16.1 |
| CAT | 1000 | 193.5 | 9.5 | <0.01 | 20.4 |
| MCA | 1 | 13.0 | 15.0 | n.s. | 0.9 |
| MCA | 10 | 195.5 | 15.0 | <0.01 | 13.0 |
| MCA | 100 | 190.5 | 15.0 | <0.01 | 12.7 |
| MCA | 1000 | 192.0 | 15.0 | <0.01 | 12.8 |
| ECA | 1 | 16.5 | 9.0 | <0.05 | 1.8 |
| ECA | 10 | 185.5 | 9.0 | <0.01 | 20.6 |
| ECA | 100 | 192.5 | 9.0 | <0.01 | 21.4 |
| ECA | 1000 | 196.5 | 9.0 | <0.01 | 21.8 |
| DMB | 10 | 12.5 | 9.5 | n.s. | 1.3 |
| DMB | 100 | 12.5 | 9.5 | n.s. | 1.3 |
| DMB | 1000 | 196.0 | 9.5 | <0.01 | 20.6 |
| DMT | 10 | 7.0 | 8.5 | n.s. | 0.8 |
| DMT | 100 | 106.0 | 8.5 | <0.01 | 12.5 |
| DMT | 1000 | 199.5 | 8.5 | <0.01 | 23.5 |
| DMS | 10 | 11.5 | 10.0 | n.s. | 1.2 |
| DMS | 100 | 188.5 | 12.5 | <0.01 | 15.1 |
| DMS | 1000 | 200.0 | 10.0 | <0.01 | 20.0 |
| ADB | 10 | 28.5 | 10.0 | <0.05 | 2.9 |
| ADB | 100 | 184.5 | 16.5 | <0.01 | 11.2 |
| ADB | 1000 | 194.0 | 10.0 | <0.01 | 19.4 |
| GUA | 100 | 13.0 | 13.0 | n.s. | 1.0 |
| GUA | 1000 | 51.5 | 12.5 | <0.01 | 4.1 |
| MMP | 10 | 10.5 | 12.0 | n.s. | 0.9 |
| MMP | 100 | 63.0 | 8.5 | <0.01 | 7.4 |
| MMP | 1000 | 200.5 | 10.0 | <0.01 | 20.1 |
| EGU | 10 | 11.5 | 10.0 | n.s. | 1.2 |
| EGU | 100 | 184.0 | 8.5 | <0.01 | 21.6 |
| EGU | 1000 | 181.5 | 14.0 | <0.01 | 13.0 |
| MVP | 10 | 22.0 | 10.0 | <0.05 | 2.2 |
| MVP | 100 | 148.0 | 12.5 | <0.01 | 11.8 |
| MVP | 1000 | 191.5 | 10.0 | <0.01 | 19.2 |
| MAN | 100 | 17.0 | 24.5 | n.s. | 0.7 |
| MAN | 1000 | 8.5 | 14.0 | n.s. | 0.6 |
| EAN | 100 | 11.0 | 14.0 | n.s. | 0.8 |
| EAN | 1000 | 22.5 | 14.0 | n.s. | 1.6 |
| VAN | 100 | 16.5 | 8.5 | <0.05 | 1.9 |
| VAN | 1000 | 182.5 | 10.0 | <0.01 | 18.3 |
| EST | 100 | 14.0 | 9.0 | n.s. | 1.6 |
| EST | 1000 | 181.5 | 12.5 | <0.05 | 14.5 |
“P” indicates the statistical significance of the difference between treatment and negative control (n.s. = no statistically significant difference). “Treatment/negative control” represents the ratio between the treatment and negative control medians. The results of three independent replicates of eugenol from [23] are reported as a reference (EUG 1, EUG 2, EUG 3).